首页> 美国卫生研究院文献>Journal of Translational Medicine >Distinct alterations of CD68+CD163+ M2-like macrophages and myeloid-derived suppressor cells in newly diagnosed primary immune thrombocytopenia with or without CR after high-dose dexamethasone treatment
【2h】

Distinct alterations of CD68+CD163+ M2-like macrophages and myeloid-derived suppressor cells in newly diagnosed primary immune thrombocytopenia with or without CR after high-dose dexamethasone treatment

机译:大剂量地塞米松治疗后新诊断的原发性免疫性血小板减少症伴或不伴CR的CD68 + CD163 + M2类巨噬细胞和髓样抑制细胞的明显改变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundAlthough impaired myeloid-derived suppressor cells (MDSCs) recently have been studied in immune thrombocytopenia (ITP), another myeloid-derived cell population signified as M2 macrophages has not been investigated properly in ITP patients. In the present study, we intended to determine the features of circulating M2-like macrophages, to examine its relationship with MDSCs, and to explore their prognostic values in ITP.
机译:背景技术尽管最近在免疫性血小板减少症(ITP)中研究了受损的髓样来源的抑制细胞(MDSC),但尚未对ITP患者中的M2巨噬细胞进行研究,这是另一个髓样来源的细胞群体。在本研究中,我们打算确定循环的M2样巨噬细胞的特征,检查其与MDSC的关系,并探讨其在ITP中的预后价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号